ClinicalTrials.gg
RecruitingNCT06895291ONCO-MRIUpdated Mar 30, 2025

Whole Body MRI in Oncology

An observational study in Lymphoma, Advanced Prostate Cancer and Advanced Breast Cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 158 studies in Lymphoma with a site in Italy — 29 open to participants now, 47 under way, 12 of them phase 3. Lymphoma · Italy.

Planned enrollment
4th of 23
1,000 · median 127
Started
2023
with 8 others
Observational
23 of 158
9 open now
Primary completion
2028-10
later than 36 of 46 live
Registered
155th of 158
by date

Among the 158 studies in Lymphoma with a site in Italy, this one is the 4th largest by planned enrollment of the 23 observational ones that give a count, is one of 9 that started in 2023, is one of 23 observational ones, reaches primary completion later than 36 of the 46 other live ones, and was the 155th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

29 of the 158 studies in Lymphoma with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Lymphoma with a site in Italy, or all of them as a file.
02

Study summary

Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.

Read the detailed description

Whole Body-Magnetic Resonance Imaging (WB-MRI) is a radiation-free and, usually, contrast administration-free imaging method for detecting bone and soft tissue pathology. It's part of the "next generation imaging techniques" combining high quality morphological images with "functional" information on diffusivity of water molecules through diffusion- weighted sequences (DWI).

Nowadays WB-MRI has been introduced in several guidelines in oncological settings, in particular for staging and relapse in patients affected by monoclonal plasma cell disorders, screening in patients with cancer predisposition syndromes (Li fraumeni syndrome, hereditary paraganglioma / pheochromocytoma syndrome, neurofibromatosis) and staging and follow-up of cancer patients affected by predominant bone metastatic pattern, particularly advanced prostate cancer and breast cancer.

The current limit on the diffusion of the technique is that it is not widely available as it requires an optimal set up of both the machine with specific sequences and the acquisition protocol, as well as dedicated, trained staff.

DWI is emerging as a core sequence of WB-MRI protocols for disease assessment because of its sensitiveness to tissue cellularity and cell viability offering excellent lesion-to-background contrast and quantification of the degree of water motion by calculation of the apparent diffusion coefficient (ADC); changes in ADC can reflect variations in cellularity. Fat-Fraction (FF) is another emerging sequence for tissue characterization that quantifies the relative amount of fat. A better investigation of these novel sequences can maximize sensitivity and specificity in order to improve our understanding of diseases assessment.

The aim of this observational study is to evaluate whether WB-MRI allows an improvement in identification of site of tumour disease or earlier progression in comparison to other methodologies that are nowadays the standard of care due to their widespread availability in hospitals and quicker execution, particularly Bone Scintigraphy (BS) Computed Tomography (CT), Positron Emission Tomography/Computed Tomography (PET/CT) .

03

Conditions studied

  • Lymphoma
  • Advanced Prostate Cancer
  • Advanced Breast Cancer
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Multiple Myeloma
  • Multiple Myeloma

Keywords

  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering multiple myeloma
  • Multiple myeloma
  • Advanced Breast Cancer
  • Advanced Prostate Cancer
  • Lymphoma
  • Whole Body-Magnetic Resonance Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The following patients groups will be prospectively enrolled:

  • Patients affected by Monoclonal plasma cell disorders (monoclonal gammopathy of undertermined significance-MGUS, Smoldering multiple myeloma- SMM, Multiple myeloma-MM).
  • Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (CT, PET/CT, BS).
  • Patients affected by Lymphomas.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.
  • Participant is willing and able to give for participation in the study.
  • Male or Female, aged ≥ 18 years.
  • greater than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Patients with MRI-unsafe prostheses and devices.
  • Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients affected by Monoclonal plasma cell disorders

    Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM).

    Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)

  • Patients affected by advanced prostate cancer (APC) or advanced breast cancer (ABC)

    Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (Computed tomography (CT), Positron Emission Computed Tomography (PET/CT), Bone Scintigraphy (BS)).

    Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)

  • Patients affected by Lymphomas.

    Patients affected by Lymphomas.

    Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)

Interventions

  • Diagnostic testWhole Body-Magnetic Resonance Imaging (WB-MRI)

    This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed: * at staging * at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients.

06

What researchers measure

Primary outcomes

  1. To evaluate whether WB-MRI allows a better evaluation of bone marrow involvement and/or soft tissue lesions in different kind of pathologies in comparison to other standard imaging modalities.

    To evaluate the accuracy of WB-MRI in terms of: Myeloma: pattern of bone marrow or soft tissues involvement (Negative /Micronodular/ diffuse/focal/ focal on diffuse/ extra and perimedullary disease)

    Time frame: 36 months

  2. To evaluate whether WB-MRI allows a better evaluation of bone marrow involvement and/or soft tissue lesions in different kind of pathologies in comparison to other standard imaging modalities.

    To evaluate the accuracy of WB-MRI in terms of: -Metastatic breast cancer an Metastatic prostate cancer: Number of lesions for oligometastatic patients or diffuse pattern for diffuse bone marrow involvement

    Time frame: 36 months

  3. To evaluate whether WB-MRI allows a better evaluation of bone marrow involvement and/or soft tissue lesions in different kind of pathologies in comparison to other standard imaging modalities.

    To evaluate the accuracy of WB-MRI in terms of: -Lymphoma:number of lesions will be assessed.

    Time frame: 36 months

  4. To evaluate whether WB-MRI allows a better evaluation of bone marrow involvement and/or soft tissue lesions in different kind of pathologies in comparison to other standard imaging modalities.

    To evaluate the accuracy of WB-MRI in terms of: -Lymphoma:diameters of lesions will be assessed.

    Time frame: 36 months

  5. To evaluate whether WB-MRI allows earlier identification of disease progression in comparison to other standard methodologies and to assess different patterns of response, stable disease, and progression that can be observed on WB-MRI.

    Pattern of response/progression will be determined in terms of: -Myeloma:Myeloma Response Assessment and Diagnosis System (MY-RADS) criteria will be applied on WB-MRI whereas n.of lesions and lesion uptake Standardized Uptake Value (SUV) variations will be used to evaluate PET-CT response.

    Time frame: 36 months

  6. To evaluate whether WB-MRI allows earlier identification of disease progression in comparison to other standard methodologies and to assess different patterns of response, stable disease, and progression that can be observed on WB-MRI.

    Pattern of response/progression will be determined in terms of: -Metastatic prostate cancer and Metastatic breast cancer: soft tissue response and progression on CT will be assessed according to RECIST 1.1guidelines. Definitions of complete and partial response or progression for bone lesions on CT and/or BS have been adopted from MD Anderson (MDA) criteria for ABC and from Prostate Cancer Working Group3 (PCWG3) for APC.

    Time frame: 36 months

  7. To evaluate whether WB-MRI allows earlier identification of disease progression in comparison to other standard methodologies and to assess different patterns of response, stable disease, and progression that can be observed on WB-MRI.

    Pattern of response/progression will be determined in terms of: -Lymphoma:for Contrast-Enhanced Computed Tomography (CE-CT) and PET-CT Lugano criteria or Lymphoma Response to Immunomodulatory Therapy Criteria criteria will be used

    Time frame: 36 months

  8. To evaluate whether WB-MRI allows earlier identification of disease progression in comparison to other standard methodologies and to assess different patterns of response, stable disease, and progression that can be observed on WB-MRI.

    Pattern of response/progression will be determined in terms of: -Lymphoma:for the diameter evaluation of max 5 lymphnodes or lesion integrated with apparent diffusion coefficient (ADC) evaluation will be applied on WB-MRI.

    Time frame: 36 months

  9. To evaluate how WB-MRI, added to other imaging modalities, alters decision making and management of patients.

    The number of times a patient treatment's course was changed by clinicians after evidences provided by WB-MRI investigations as per clinical routine.

    Time frame: 36 months

Secondary outcomes

  1. Identification of imaging biomarkers for precise disease differentiation or for response prediction.

    We will evaluate the discriminating performance of imaging features for differentiating between smouldering multiple myeloma and multiple myeloma.

    Time frame: 36 months

  2. Identification of imaging biomarkers for precise disease differentiation or for response prediction.

    We will assess the discriminating performance of imaging features for differentiating between invasive lobular carcinoma and invasive ductal carcinoma.

    Time frame: 36 months

  3. Identification of imaging biomarkers for precise disease differentiation or for response prediction.

    We will examine the discriminating performance of imaging features for distinguishing between the heterogeneous histotype characteristics of lymphoma.

    Time frame: 36 months

07

Study locations

2 of 3 sites recruiting
  • IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola
    Bologna, BO 40138, Italy
    Recruiting
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
    Meldola, FC 47014, Italy
    Recruiting
  • IRCCS Istituto Europeo di Oncologia S.r.l.
    Milano, MI 20141, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2028, 60 months after the start.

Of 141 non-industry observational studies under Lymphoma, half reached primary completion within 90 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 269. This study's planned 60 months is below that.

Counting every sponsor, half of 160 studies reached it within 82 months; a quarter within 39 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 26, 2025
StartActual
Oct 26, 2023
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2031
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895291
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Oct 26, 2023
Primary completion
Oct 2028 (estimated)
Completion
Oct 2031 (estimated)
Last update
Mar 30, 2025

Study contacts

Oriana Nanni
Contact
cc.ubsc@irst.emr.it
+390543739266
Bernadette Vertogen
Contact
cc.ubsc@irst.emr.it
+390544286058
Alice Rossi
principal investigator · IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion